Edition:
United States

Cerus Corp (CERS.O)

CERS.O on Consolidated Issue listed on NASDAQ Global Market

6.21USD
30 Sep 2016
Change (% chg)

$0.09 (+1.47%)
Prev Close
$6.12
Open
$6.13
Day's High
$6.25
Day's Low
$6.01
Volume
923,114
Avg. Vol
1,150,714
52-wk High
$7.64
52-wk Low
$4.27

CERS.O

Chart for CERS.O

About

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to... (more)

Overall

Beta: 1.99
Market Cap(Mil.): $628.58
Shares Outstanding(Mil.): 102.71
Dividend: --
Yield (%): --

Financials

  CERS.O Industry Sector
P/E (TTM): -- 37.20 36.83
EPS (TTM): -0.66 -- --
ROI: -58.48 12.50 13.93
ROE: -70.71 14.81 14.84

BRIEF-FDA recommends use of pathogen reduction for universal Zika risk reduction of blood components

* Fda's new recommendation for universal zika risk reduction of blood components includes use of pathogen reduction

Aug 29 2016

BRIEF-Cerus Q2 loss per share $0.18

* Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S

Aug 04 2016

UPDATE 1-FDA takes steps to protect blood supply in Florida amid Zika probe

CHICAGO, July 28 The U.S. Food and Drug Administration has ordered blood banks in Florida's two most densely populated counties to stop collecting blood as health officials determine whether Zika has begun transmission in the continental United States.

Jul 28 2016

BRIEF-Cerus Corp says Health Canada has approved Intercept blood system for plasma

* Says health canada has approved intercept blood system for plasma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 23 2016

BRIEF-Cerus Corp reports Q1 loss per share $0.17

* Q1 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 03 2016

Competitors

  Price Chg
Terumo Corp (4543.T) ¥3,865 -90.00
Grifols SA (GRLS.MC) €19.18 -0.03
Grifols SA (GRLSbn.MC) €14.26 -0.17

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Jefferson Research
$20.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.